Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30107% above fair value
$3.78−0.12 (-3.08%)
Close on Nov 18, 2026Market cap $1.33BP/E –Yield –
Nuvation Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Nuvation Bio's operating income for the twelve months ending Jun 30, 2026 was -$137.63M. For fiscal 2025 it was -$213.06M. The highest annual figure on record is -$43.55M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$213.06M | – |
| FY2024 | Dec 31, 2024 | -$592.63M | – |
| FY2023 | Dec 31, 2023 | -$99.82M | – |
| FY2022 | Dec 31, 2022 | -$119.73M | – |
| FY2021 | Dec 31, 2021 | -$93.32M | – |
| FY2020 | Dec 31, 2020 | -$43.55M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$51.04M | – |
| Q1 FY2026 | Mar 31, 2026 | $3.88M | – |
| Q4 FY2025 | Dec 31, 2025 | -$34.04M | – |
| Q3 FY2025 | Sep 30, 2025 | -$56.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$63.59M | – |
| Q1 FY2025 | Mar 31, 2025 | -$59.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$53.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$48.10M | – |
| Q2 FY2024 | Jun 30, 2024 | -$470.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$20.20M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.83M | – |
| Q3 FY2023 | Sep 30, 2023 | -$26.34M | – |
| Q2 FY2023 | Jun 30, 2023 | -$26.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.52M | – |
| Q4 FY2022 | Dec 31, 2022 | -$24.34M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.34M | – |
| Q2 FY2022 | Jun 30, 2022 | -$37.87M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.19M | – |
| Q4 FY2021 | Dec 31, 2021 | -$29.61M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.79M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.43M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.48M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.77M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.55M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.02M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.22M | – |
See a number that looks wrong?